Abbott’s Aveir VR Leadless Pacemaker System Receives the US FDA’s Approval for the Treatment of Slow Heart Rhythms
Shots:
- The approval was based on the P-II (LEADLESS II) IDE study evaluating Aveir VR in patients with abnormal heart rhythms. The results showed the device met its pre-specified 1EPs
- The device has been placed directly inside the heart's right ventricle through a minimally invasive procedure for slow heart rhythms & has a unique mapping capability to assess correct positioning before placement
- Aveir VR has an increased projected battery life that can be two times longer over other commercially available leadless pacemakers using ISO standard settings. Additionally, The device has the potential to be retrieved if the therapy needs to evolve or be replaced
Ref: Abbott | Image: Abbott
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
